Clinical Trial: A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07291076) titled 'A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)' on Dec. 17.

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Study Start Date: Feb. 09, 2026

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma (HCC)

Intervention: DRUG: Pumitamig

Specified dose on specified days

DRUG: Ipilimumab

Speci...